Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

November 19, 2024

Ryan Haumschild, PharmD, MS, MBA, CPEL
JoAnn V. Pinkerton, MD, FACOG, MSCP

Opinion

Video

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings regarding its efficacy in reducing the frequency and severity of vasomotor symptoms (VMS) compared with other treatments, as well as its impact on quality of life and the speed at which patients experienced symptom improvement.

EP: 1.Understanding the Burden of Menopausal Vasomotor Symptoms

EP: 2.Barriers to VMS Treatment and Impact on Long-Term Health

EP: 3.Improving Access and Equity in VMS Treatment

EP: 4.Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP: 5.Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP: 6.Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

Now Viewing

EP: 7.Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP: 8.Safety Profiles of Neurokinin-Targeted Therapies for VMS

Video content above is prompted by the following:

(PINKERTON) Elinzanetant was studied in the OASIS 1 and 2 trials, and new data on OASIS 3 were just presented at The Menopause Society’s 2024 Annual Meeting. What was the methodology of these studies?
(SMITH) What are the key findings from the OASIS trials in terms of the reduction in frequency and severity of VMS, and how do these compare with other hormonal and nonhormonal treatments?
1. How did elinzanetant impact quality of life for women with severe VMS in the OASIS trials?
2. How quickly did patients experience an improvement in symptoms?
(PINKERTON) What notable adverse events were observed in the OASIS trials with elinzanetant?
(FIFFICK) How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments?